Skip to main content
. 2019 May 26;3(3):515–527. doi: 10.1002/rth2.12207

Figure 3.

Figure 3

Kappa agreement among aPL assays at manufacturer and in‐house cutoff values. aβ2GPI, anti‐β2 glycoprotein I antibodies; aCL, anticardiolipin antibodies; method A, p (n + 1), where p indicates the percentile and n indicates the sample size; method B, pn + 0.5, where p indicates the percentile and n indicates the sample size; P, percentile; TM, Tietjen‐Moore. Dotted lines represent kappa agreement at manufacturers’ cutoff values